SIGA TECHNOLOGIES (SIGA) Company Report

SIGA delivered $88 million in product revenues and $23 million in net income for 2025, with a fully diluted income per share of $0.32. The company ended the year with a strong cash balance of approximately $155 million and no debt.
Product revenues for 2025 included $53 million of oral TPOXX and $26 million of IV TPOXX delivered to the U.S. Strategic National Stockpile, along with $6 million from international oral TPOXX sales. Approximately $26 million of U.S. government orders for IV TPOXX are outstanding and expected to be delivered in 2026.
SIGA received a $13 million order from a country in the Asia-Pacific region in early 2026, which is a multi-year contract with a repeat customer. The EMA's CHMP is expected to issue its recommendation in March regarding the marketing authorization for Tecovirimat SIGA, with an expectation to confirm the positive benefit-risk balance for smallpox and related indications, while recommending withdrawal of the mpox indication.
The company is targeting an FDA submission for the post-exposure prophylaxis (PEP) indication in the next 12 months and has initiated a Phase 1 study for a pediatric oral suspension formulation, with results expected in the second half of 2026. SIGA plans to remain disciplined and flexible in its capital management strategy, with discussions regarding special cash dividends typically occurring between March and May.

3 days ago

Transcript

SIGA Technologies Reports Q4 and Full-Year 2025 Financial Results and Strategic Updates

SIGA

Earnings

New Projects/Investments

SIGA delivered solid financial results for 2025, with product revenues totaling approximately $88 million and net income of approximately $23 million, resulting in fully diluted income per share of $0.32. The company concluded 2025 with a strong cash balance of approximately $155 million and no debt.
Product deliveries in 2025 included $53 million of oral TPOXX and $26 million of IV TPOXX to the U.S. Strategic National Stockpile, alongside $6 million from international oral TPOXX sales. As of December 31, 2025, $26 million of U.S. government IV TPOXX orders are outstanding, with delivery targeted for 2026.
The company secured $27 million in funding for pediatric formulation development and IV technology transfer. Internationally, SIGA received a $13 million multi-year order from a repeat customer in the Asia-Pacific region.
The EMA's CHMP is expected to issue its recommendation in March regarding Tecovirimat SIGA's marketing authorization, with expectations to confirm the positive benefit-risk for smallpox but recommend withdrawal of the mpox indication. SIGA is also targeting an FDA submission for the post-exposure prophylaxis (PEP) indication in the next 12 months and initiated a Phase I study for a pediatric oral suspension formulation with results expected in the second half of 2026.

3 days ago

Transcript

SIGA Technologies Announces Q4 and Full-Year 2025 Results

SIGA

Earnings

New Projects/Investments

Guidance Update

SIGA Technologies reported $88 million in product revenues for 2025, primarily driven by $53 million from oral TPOXX and $26 million from IV TPOXX delivered to the U.S. Strategic National Stockpile, along with $6 million from international oral TPOXX sales.
The company concluded 2025 with a strong financial position, holding approximately $155 million in cash and no debt, and reported a fully diluted income per share of $0.32.
As of December 31, 2025, $26 million of U.S. government IV TPOXX orders remain outstanding, with delivery targeted for 2026, and SIGA recently secured a $13 million multi-year order from a repeat customer in the Asia-Pacific region.
The EMA's Committee for Medicinal Products for Human Use (CHMP) is expected to recommend confirmation of Tecovirimat SIGA's positive benefit-risk for smallpox, cowpox, and vaccinia complications, but withdrawal of the mpox indication, in March 2026.
Strategic initiatives include targeting an FDA submission for the post-exposure prophylaxis (PEP) indication within the next 12 months and initiating a Phase 1 study for a pediatric oral suspension formulation, with results anticipated in the second half of 2026.

3 days ago

Transcript

SIGA Technologies Inc. Reports Q4 and Full Year 2025 Financial Results

SIGA

Earnings

New Projects/Investments

Demand Weakening

SIGA Technologies Inc. reported $88.0 million in TPOXX product revenues and $94.6 million in total revenues for the full year ended December 31, 2025, with a net income of $23.3 million and diluted earnings per share of $0.32.
For the fourth quarter ended December 31, 2025, the company reported $2.2 million in product sales, resulting in a net loss of $5.4 million and a diluted loss per share of $(0.08).
In January 2026, SIGA received a $13 million international procurement order for oral TPOXX from a customer in the Asia Pacific region.
During 2025, the company secured $27 million in additional U.S. Government funding for development activities and received a $26 million procurement order for IV TPOXX from the U.S. Government in March 2025.

3 days ago

8-K

SIGA Technologies Reports Q4 and Full-Year 2025 Financial Results

SIGA

Earnings

Guidance Update

SIGA Technologies reported full-year 2025 total revenues of $94.6 million and net income of $23.3 million, resulting in diluted earnings per share of $0.32.
For the fourth quarter of 2025, the company recorded total revenues of $3.8 million and a net loss of $5.4 million, with a diluted loss per share of $0.08.
In January 2026, SIGA secured a $13 million procurement order for oral TPOXX from an Asia Pacific customer, with deliveries anticipated in 2026.
The company expects the European Medicine Agency's CHMP to recommend withdrawal of the mpox indication for tecovirimat in March 2026, while maintaining other approved indications.

3 days ago

Press Release

SIGA Reports Q3 2025 Financial Results and Strategic Updates

SIGA

Earnings

Guidance Update

Dividends

Share Buyback

For the nine months ended September 30, 2025, SIGA reported product revenue of approximately $86 million, including $53 million from oral TPOXX and $26 million from IV TPOXX sales under the BARDA contract, and $6 million from international oral TPOXX sales. The company recorded a net loss of approximately $6 million for Q3 2025, following a strong Q2 2025 with $79 million in product revenues.
As of September 30, 2025, SIGA maintained a strong cash balance of approximately $172 million with no debt. Since 2020, the company has returned approximately $230 million to shareholders through dividends and share buybacks.
There is $26 million in outstanding U.S. government orders for IV TPOXX, expected for delivery in 2026. SIGA anticipates multiple international sales in 2026 based on ongoing discussions and interest from key stakeholders.
The company is targeting an FDA submission for the TPOXX post-exposure prophylaxis (PEP) indication in 2026 and an IND submission for its pediatric program by year-end 2025. SIGA continues to engage with the U.S. government regarding future TPOXX procurement, despite potential delays due to the government shutdown.

Nov 6, 2025, 9:30 PM

Transcript

SIGA Technologies Reports Q3 2025 Financial Results and Business Updates

SIGA

Earnings

Dividends

New Projects/Investments

SIGA Technologies reported $90.8 million in total revenues and $28.7 million in net income for the nine months ended September 30, 2025, compared to $57.3 million and $13.5 million, respectively, for the same period in 2024. For the third quarter of 2025, the company recorded a net loss of $6.4 million and diluted loss per share of $(0.09) on total revenues of $2.6 million.
For the first nine months of 2025, the company generated $53 million from oral TPOXX and $26 million from IV TPOXX deliveries to the U.S. Strategic National Stockpile, and received a $26 million procurement order for IV TPOXX from the U.S. Government in March 2025.
The BARDA 19C contract was modified in Q2 2025 to add $27 million in development funding for TPOXX pediatric development and manufacturing activities.
In January 2025, TPOXX received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, and complications following smallpox vaccination. Additionally, a special cash dividend of $0.60 per share was declared on April 8, 2025, and paid on May 15, 2025.

Nov 6, 2025, 9:06 PM

8-K

SIGMA Corp. Partner KRTL Biotech Highlights Anti-Infectives and Antibiotics Portfolio

SIGA

Product Launch

New Projects/Investments

KRTL Biotech, a majority-owned subsidiary of KRTL Holding Group Inc., is highlighting its expanded portfolio of anti-infective and antibiotic products, developed in collaboration with SIGMA Corp..
The current product line includes essential formulations such as Hostess Suspension, Positrin, and Taxonid, with SIGMA's GMP-certified facility capable of producing a broader range of therapies, including penicillin derivatives and macrolides.
These offerings align with the World Health Organization's (WHO) Model List of Essential Medicines, targeting a global anti-infectives market estimated to exceed $150 billion annually.
KRTL Biotech is evaluating regulatory pathways for select formulations to enter U.S. and other export markets, leveraging SIGMA's manufacturing capabilities in Bolivia, which contributed significantly to national pharmaceutical distribution in fiscal year 2024.